XOMA Royalty (XOMA) Competitors $25.67 -0.63 (-2.40%) Closing price 04:00 PM EasternExtended Trading$25.73 +0.06 (+0.23%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, DVAX, INVA, MNKD, NVAX, OPK, GERN, RGLS, ZBIO, and MYGNShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas BioPharma (ZBIO), and Myriad Genetics (MYGN). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA Dynavax Technologies Innoviva MannKind Novavax OPKO Health Geron Regulus Therapeutics Zenas BioPharma Myriad Genetics XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Which has preferable valuation & earnings, XOMAO or XOMA? XOMA has higher earnings, but lower revenue than XOMA Royalty. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$13.05MN/AN/AN/AN/AXOMA Royalty$28.49M10.79-$13.82M-$1.15-22.32 Do analysts rate XOMAO or XOMA? XOMA Royalty has a consensus target price of $69.50, suggesting a potential upside of 170.74%. Given XOMA Royalty's stronger consensus rating and higher possible upside, analysts plainly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is XOMAO or XOMA more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -13.04%. XOMA's return on equity of 0.00% beat XOMA Royalty's return on equity.Company Net Margins Return on Equity Return on Assets XOMAN/A N/A N/A XOMA Royalty -13.04%-12.43%-4.85% Do institutionals & insiders have more ownership in XOMAO or XOMA? 95.9% of XOMA Royalty shares are owned by institutional investors. 9.1% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer XOMAO or XOMA? In the previous week, XOMA Royalty had 2 more articles in the media than XOMA. MarketBeat recorded 2 mentions for XOMA Royalty and 0 mentions for XOMA. XOMA's average media sentiment score of 1.87 beat XOMA Royalty's score of 0.62 indicating that XOMA is being referred to more favorably in the media. Company Overall Sentiment XOMA Very Positive XOMA Royalty Positive SummaryXOMA Royalty beats XOMA on 7 of the 11 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$314.73M$2.91B$5.52B$9.41BDividend YieldN/A2.45%3.80%4.04%P/E RatioN/A19.8828.0419.84Price / Sales10.79305.11429.5399.59Price / CashN/A43.1635.8457.94Price / Book3.697.678.125.65Net Income-$13.82M-$55.28M$3.25B$258.00M7 Day Performance-5.42%2.50%0.97%2.09%1 Month Performance4.26%11.70%7.36%11.13%1 Year Performance-6.35%4.89%31.31%18.40% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty3.8175 of 5 stars$25.67-2.4%$69.50+170.7%-8.4%$314.73M$28.49M-22.3210XOMAOXOMAN/A$25.50+0.0%N/A+2.7%$0.00$13.05M0.0010Positive NewsDVAXDynavax Technologies4.3821 of 5 stars$10.74+1.5%$24.00+123.5%+0.0%$1.29B$294.62M-20.65350INVAInnoviva4.0829 of 5 stars$19.58+4.3%$40.33+106.0%+13.9%$1.23B$358.71M-19.39100Analyst RevisionGap UpMNKDMannKind2.6384 of 5 stars$4.03+6.9%$10.33+156.4%-32.8%$1.22B$285.50M40.30400News CoverageAnalyst UpgradeInsider TradeAnalyst RevisionNVAXNovavax4.3379 of 5 stars$6.97+1.9%$17.00+143.9%-55.8%$1.13B$1.21B2.631,990OPKOPKO Health4.0156 of 5 stars$1.34-0.7%$2.75+105.2%-2.8%$1.06B$713.10M-19.142,997Positive NewsGERNGeron3.46 of 5 stars$1.34+1.5%$4.61+244.1%-72.9%$853.47M$116.29M-6.3870News CoverageRGLSRegulus Therapeutics1.6649 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830ZBIOZenas BioPharma1.5936 of 5 stars$12.82+14.7%$36.67+186.0%N/A$536.26M$5M-3.61N/AMYGNMyriad Genetics4.5811 of 5 stars$5.22-2.2%$14.38+175.6%-82.2%$481.16M$831.30M-4.662,700News CoveragePositive News Related Companies and Tools Related Companies XOMA Alternatives Dynavax Technologies Alternatives Innoviva Alternatives MannKind Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Zenas BioPharma Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XOMA Stock Alerts